Plain-English translation of NCT06042387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Researchers at Mount Sinai Hospital are trying to understand why some people develop inflammatory bowel disease (IBD)—a chronic condition affecting the intestines—by studying the genes of people with the disease and comparing them to healthy volunteers. By analyzing DNA from blood or saliva samples, the study team hopes to discover which genetic variations make certain people more likely to develop IBD. This knowledge could eventually lead to better ways to diagnose, prevent, or treat these conditions.
Inflammatory bowel disease is becoming more common, and doctors don't yet fully understand what causes it. This research aims to identify the genetic factors that put people at risk, which could help develop better treatments and prevention strategies in the future.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be asked to provide either a blood sample or a saliva sample—whichever is easier for you. The study team will also review your medical records to confirm your diagnosis if you have IBD. There are no ongoing visits or long-term commitments; the main participation is the one-time sample collection.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Canada
Sponsor
Mount Sinai Hospital, Canada
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment target
~150 participants
Started
May 2022
Primary completion
May 2027
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Joanne Stempak, MSc
Sinai Health System
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.